North America Cardiac Resynchronization Therapy Market Outlook, 2031

Market Drivers

• Rising prevalence and healthcare burden of heart failure: Heart failure remains the primary driver of the North American CRT market, supported by a large and expanding patient population requiring advanced cardiac care. According to the American Heart Association, nearly 6.7 million adults in the United States are living with heart failure, with the number projected to exceed 8 million by 2030. In Canada, 134,460 new heart failure cases were reported during 2023–2024, while 70,590 hospitalizations accounted for 2.3% of all hospital admissions. The growing clinical burden continues to increase demand for CRT among appropriately selected patients.
• Advanced cardiovascular infrastructure and specialized cardiac care: North America benefits from a highly developed network of tertiary hospitals, electrophysiology laboratories, and specialized heart failure centers, enabling broader access to CRT implantation and follow-up care. The United States performs one of the world's highest volumes of implantable cardiac device procedures, supported by mature reimbursement systems and advanced diagnostic capabilities. In Canada, specialized cardiac centers continue to strengthen CRT adoption, while Mexico is expanding access through advanced institutions, including internationally accredited heart failure centers, improving long-term regional market growth.

Market Challenges

• Limited CRT-eligible population despite high heart failure prevalence: Although North America has millions of heart failure patients, only a relatively small proportion meets guideline-based criteria for CRT implantation. Of the 6.7 million U.S. heart failure patients, eligibility depends on factors including reduced left ventricular ejection fraction, QRS duration, symptom severity, and optimized medical therapy. This significantly narrows the addressable market, making accurate patient identification and referral essential for sustained CRT market growth across the region.
• High treatment costs and unequal access to specialized care: CRT therapy involves substantial costs associated with implantable devices, hospitalization, implantation procedures, programming, and long-term monitoring. Geographic disparities further limit adoption, particularly in rural and remote regions of Canada and underserved areas of Mexico. In Canada, heart failure patients recorded an average hospital stay of 9.6 days, highlighting the healthcare resource burden, while variations in reimbursement, insurance coverage, and availability of electrophysiology specialists continue to influence procedure volumes across North America.

Market Trends

• Growing adoption of remote monitoring and connected cardiac care (CLIA): Remote monitoring is becoming a standard component of CRT management across North America, supported by the region's advanced digital healthcare infrastructure. Modern CRT devices increasingly integrate wireless connectivity, device diagnostics, and physiological monitoring, allowing clinicians to detect potential complications earlier while reducing unnecessary in-person visits. With more than 6.7 million heart failure patients in the United States requiring long-term follow-up, connected care solutions are playing an increasingly important role in improving clinical outcomes and healthcare efficiency.
• Integration of microfluidic Lab-on-a-Chip designs: Healthcare providers across North America are increasingly emphasizing personalized CRT programming and earlier identification of eligible patients through ECG, echocardiography, and advanced imaging technologies. Clinical decision-making now focuses on individual patient characteristics, including electrical conduction abnormalities and ventricular function, to improve response rates. With U.S. heart failure cases projected to exceed 8 million by 2030 and Canada reporting 134,460 new cases in 2023–2024, optimizing patient selection is becoming a major trend supporting future CRT adoption.